Salarius Pharmaceuticals, Inc.
SLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $770 | $7,174 | $15,837 | $8,549 |
| G&A Expenses | $4,964 | $5,721 | $7,138 | $6,105 |
| SG&A Expenses | $4,964 | $5,721 | $7,138 | $6,105 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $8,866 | -$1,840 |
| Operating Expenses | $5,734 | $12,895 | $31,841 | $12,813 |
| Operating Income | -$5,734 | -$12,895 | -$31,841 | -$12,813 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $159 | $352 | $233 | $45 |
| Pre-Tax Income | -$5,576 | -$12,543 | -$31,608 | -$12,768 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,576 | -$12,543 | -$31,608 | -$12,768 |
| % Margin | – | – | – | – |
| EPS | -86.85 | -0.057 | -221.55 | -930 |
| % Growth | -152,268.4% | 100% | 76.2% | – |
| EPS Diluted | -86.85 | -0.057 | -221.55 | -930 |
| Weighted Avg Shares Out | 64 | 219 | 142 | 14 |
| Weighted Avg Shares Out Dil | 64 | 219 | 142 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $159 | $352 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $10 | $7 | $19 |
| EBITDA | -$5,730 | -$12,885 | -$22,969 | -$12,794 |
| % Margin | – | – | – | – |